Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Change in Receivables: 2012-2024

Historic Change in Receivables for Gyre Therapeutics (GYRE) over the last 7 years, with Dec 2024 value amounting to $1.1 million.

  • Gyre Therapeutics' Change in Receivables rose 177.17% to $1.1 million in Q4 2024 from the same period last year, while for Dec 2024 it was -$2.0 million, marking a year-over-year increase of 18.42%. This contributed to the annual value of $5.3 million for FY2024, which is 1944.56% up from last year.
  • Per Gyre Therapeutics' latest filing, its Change in Receivables stood at $1.1 million for Q4 2024, which was up 177.17% from -$1.5 million recorded in Q4 2023.
  • Gyre Therapeutics' 5-year Change in Receivables high stood at $1.8 million for Q4 2020, and its period low was -$13.6 million during Q1 2020.
  • Its 3-year average for Change in Receivables is -$489,250, with a median of -$809,000 in 2022.
  • Per our database at Business Quant, Gyre Therapeutics' Change in Receivables tumbled by 158.45% in 2022 and then surged by 177.17% in 2024.
  • Gyre Therapeutics' Change in Receivables (Quarterly) stood at $1.8 million in 2020, then crashed by 59.95% to $704,000 in 2021, then slumped by 158.45% to -$564,000 in 2022, then reached -$1.5 million in 2023, then soared by 177.17% to $1.1 million in 2024.
  • Its Change in Receivables stands at $1.1 million for Q4 2024, versus -$1.5 million for Q4 2023 and -$564,000 for Q2 2022.